146 related articles for article (PubMed ID: 31202091)
1. Identification of novel small molecules against GSK3β for Alzheimer's disease using chemoinformatics approach.
Shukla R; Munjal NS; Singh TR
J Mol Graph Model; 2019 Sep; 91():91-104. PubMed ID: 31202091
[TBL] [Abstract][Full Text] [Related]
2. Identification of small molecules against cyclin dependent kinase-5 using chemoinformatics approach for Alzheimer's disease and other tauopathies.
Shukla R; Singh TR
J Biomol Struct Dyn; 2022 Apr; 40(6):2815-2827. PubMed ID: 33155527
[TBL] [Abstract][Full Text] [Related]
3. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches.
Shukla R; Singh TR
J Genet Eng Biotechnol; 2021 May; 19(1):61. PubMed ID: 33945025
[TBL] [Abstract][Full Text] [Related]
6. Identifying potential Alzheimer's disease therapeutics through GSK-3β inhibition: A molecular docking and dynamics approach.
Mohammadi Y; Emadi R; Maddahi A; Shirdel S; Morowvat MH
Comput Biol Chem; 2024 Aug; 111():108095. PubMed ID: 38805865
[TBL] [Abstract][Full Text] [Related]
7. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
8. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
9. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
Saravanan K; Hunday G; Kumaradhas P
J Biomol Struct Dyn; 2020 Mar; 38(4):957-974. PubMed ID: 30963817
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
11. Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy.
Emmanuel IA; Olotu F; Agoni C; Soliman MES
Med Hypotheses; 2019 Sep; 130():109277. PubMed ID: 31383337
[TBL] [Abstract][Full Text] [Related]
12. Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study.
Xie H; Wen H; Zhang D; Liu L; Liu B; Liu Q; Jin Q; Ke K; Hu M; Chen X
Oncotarget; 2017 Mar; 8(11):18118-18128. PubMed ID: 28179579
[TBL] [Abstract][Full Text] [Related]
13. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
Nisha CM; Kumar A; Vimal A; Bai BM; Pal D; Kumar A
J Mol Graph Model; 2016 Apr; 65():100-7. PubMed ID: 26967552
[TBL] [Abstract][Full Text] [Related]
14. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation.
Elangovan ND; Dhanabalan AK; Gunasekaran K; Kandimalla R; Sankarganesh D
J Biomol Struct Dyn; 2021 Nov; 39(18):7065-7079. PubMed ID: 32779973
[TBL] [Abstract][Full Text] [Related]
15. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
16. Rosmarinic Acid Derivatives' Inhibition of Glycogen Synthase Kinase-3β Is the Pharmacological Basis of Kangen-Karyu in Alzheimer's Disease.
Paudel P; Seong SH; Zhou Y; Park CH; Yokozawa T; Jung HA; Choi JS
Molecules; 2018 Nov; 23(11):. PubMed ID: 30413117
[TBL] [Abstract][Full Text] [Related]
17. Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs.
Balasubramaniam M; Mainali N; Bowroju SK; Atluri P; Penthala NR; Ayyadevera S; Crooks PA; Shmookler Reis RJ
Sci Rep; 2020 Oct; 10(1):18326. PubMed ID: 33110096
[TBL] [Abstract][Full Text] [Related]
18. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
Lu K; Wang X; Chen Y; Liang D; Luo H; Long L; Hu Z; Bao J
Acta Biochim Biophys Sin (Shanghai); 2018 May; 50(5):456-464. PubMed ID: 29546355
[TBL] [Abstract][Full Text] [Related]
19. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
20. In silico screening and identification of potential GSK3β inhibitors.
Daggupati T; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Aug; 38(4):279-289. PubMed ID: 29947280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
